Clinical trials: Pre-Eclampsia
Severe Preeclampsia
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia
This study evaluates the use of AMAG-423 (Digoxin Immune Fab) in addition to expectant management in the treatment of severe preeclampsia as compared to placebo.
- Trial name
- NCT03008616
- Testing
- AMAG-423 (digoxin immune fab)
- Where
- 18 sites in United States, Poland and 1 more
- Volunteers
- 58 people
- Sponsor
- AMAG Pharmaceuticals, Inc.
Pre-Eclampsia
Evaluation of the Safety of Relaxin in Preeclampsia
The purpose of this study is to determine whether different doses of recombinant human relaxin is safe when given to women with severe preeclampsia
- Trial name
- NCT00333307
- Testing
- recombinant human relaxin
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Preeclampsia
Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers
Sample Collection Study
- Trial name
- NCT02808494
- Where
- 10 sites in United States
- Volunteers
- 242 people
- Sponsor
- Illumina, Inc.
Preterm Labor, Preterm Birth
MIRACLE of LIFE Study
The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1.
- Conditions
- Preterm Labor, Preterm Birth, Preterm Birth Complication, Preterm Premature Rupture of Membrane
- Trial name
- MoL (NCT06074601)
- Testing
- Mirvie Predictive Test for Adverse Pregnancy Outcomes
- Where
- 10 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Mirvie
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
This is an open-label, single-arm, Phase Ⅰa clinical study designed to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of multiple doses of Telpegfilgrastim Injection in non-pregnant…
- Trial name
- NCT06924385
- Testing
- Telpegfilgrastim Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hypertensive Disorders of Pregnancy (HDP), Maternal Health Care
Cost-Effectiveness of an mHealth Application in Pregnancy Care
Participants will be randomly assigned to either the intervention arm (mHealth application users) or the control arm, in which participants will record their data on paper or in Excel according to standard practice or the…
- Conditions
- Hypertensive Disorders of Pregnancy (HDP), Maternal Health Care, Mobile Health Technology (mHealth), Preeclampsia (PE)
- Trial name
- Penelope (NCT07621133)
- Testing
- mHealth application Penelope, Control
- Where
- Czechia
- Volunteers
- 166 people
- Sponsor
- Principal Engineering s.r.o.
Pre-eclampsia, Preterm Birth
Maternal Serum Markers Predicting Preeclampsia At Early Gestations
This observational study aims to assess the effectiveness of a maternal blood test as a prognostic tool for predicting early pregnancy risk of preeclampsia (PE).
- Trial name
- NCT05131282
- Testing
- Blood test of PE risk, Blood test of Preterm PE risk
- Where
- 6 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- HBI Solutions Inc.
Anemia in Pregnancy, Pre-eclampsia
A Retrospective Analysis of Neevo® and NeevoDHA® Compared to a Standard Prenatal Vitamin in Anemia During Pregnancy
This study is a multi-site, retrospective chart review to determine the effect of Neevo® or NeevoDHA® (with higher folate and B12) versus standard prenatal vitamins on hemoglobin (Hgb) levels in pregnant women throughout the…
- Trial name
- NCT01193192
- Testing
- Neevo®, Prenatal vitamins
- Where
- 3 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pamlab, L.L.C.
Pre-Eclampsia
DM199 for Pregnancy Complications
This entry was submitted in error by DiaMedica Therapeutics, Inc. and was not authorized by any of the trial Investigators or study sponsor (Stellenbosch University).
- Trial name
- NCT06875141
- Testing
- DM199
- Sponsor
- DiaMedica Therapeutics Inc
Preeclampsia
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
This is an open-label, Phase Ia clinical study to evaluate the safety, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of single dose of telpegfilgrastim injection in healthy premenopausal non-pregnant…
- Trial name
- NCT06893796
- Testing
- Telpegfilgrastim Injection
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Pre-eclampsia
Sildenafil Citrate for the Treatment of Established Pre-Eclampsia
To determine the efficacy and safety of sildenafil citrate in the treatment of established pre-eclampsia
- Trial name
- NCT00141310
- Testing
- Sildenafil citrate
- Where
- 10 sites in United Kingdom
- Volunteers
- 76 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.